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While gamma delta T cell (γδTc) anticancer immunotherapies are being developed, recent
reports suggest a regulatory role for γδTc tumor-infiltrating lymphocytes. This mini-review
surveys available evidence, determines strengths and weaknesses thereof and suggest
directions for further exploration.We focus on human γδTc, as mouse and human γδTc reper-
toires differ. Regulatory γδTc are defined and compared to conventionalTregs and their roles
in health and disease (focusing in on cancer) are discussed. We contrast the suggested
regulatory roles for γδTc in breast and colorectal cancer with their cytotoxic capabilities
in other malignancies, emphasizing the context dependence of γδTc functional plasticity.
Since γδTc can be induced to exhibit regulatory properties (in some cases reversible), we
carefully scrutinize experimental procedures in published reports. As γδTc garner increas-
ing interest for their therapeutic potential, it is critical that we appreciate the full extent
of their role(s) and interactions with other cell types in both the circulation and the tumor
microenvironment. A comprehensive understanding will enable manipulation of γδTc to
improve anti-tumor efficacy and patient outcomes.
Keywords: gamma delta T cells, cancer immunotherapy, regulatory T cells, human cancer, gamma delta T cell
functional plasticity
INTRODUCTION
While those of us in the immunotherapy world tend to focus
on the anti-infection and anti-tumor properties of γδTc, we are
now beginning to appreciate that, under certain conditions, these
remarkable cells can inhibit or suppress the maturation and/or
activation of immune cells around them, leading to beneficial or
potentially pathological consequences.
A suppressor function of human γδTc was first described in
1989 by Patel and colleagues; upon in vitro stimulation with poke-
weed mitogen, most γδTc clones could suppress the generation
of Immunoglobulin(Ig)-secreting B cells by CD4+ T helper cells
treated with mitomycin C (Figure 1A) (1). Since then, regula-
tory roles for γδTc have been described in several contexts. Both
Vδ1 and Vδ2 T cell subsets (Vδ1Tc and Vδ2Tc, respectively) may
exhibit regulatory properties, albeit in different settings.
Human peripheral blood-derived γδTc displaying regulatory
properties are phenotypically different from conventional reg-
ulatory CD4+ αβ T cells (Treg). In contrast to Treg, freshly
isolated γδTc express only low levels of CD25 and cytotoxic T
lymphocyte-associated antigen (CTLA)-4, and do not express the
transcription factor forkhead box P3 (FoxP3) (2–4). Similar to
conventional αβ T cells (αβTc), CD25 is up-regulated on γδTc
after initial phytohemagglutinin (PHA) or anti-γδ TCR mono-
clonal antibody (mAb) stimulation (5). Additionally, CD25 is also
up-regulated on Vδ2Tc after stimulation with pyrophosphates
(phosphorylated antigens), which are intermediates of the iso-
prenoid pathway and induce selective expansion of Vδ2Tc within
peripheral blood mononuclear cells (PBMC) 7–10 days after ini-
tial stimulation (6, 7). Furthermore, FoxP3 expression can be
detected with PCH101 mAb but not with the more Treg-specific
259D mAb, in γδTc as well as in Treg-depleted αβTc after acti-
vation (4). FoxP3 expression as identified by PCH101 mAb does
not correlate with suppressive function (8, 9). In addition, the
transcription factor Helios, which is highly expressed by Treg, is
constitutively expressed in roughly one-third of freshly isolated
γδTc (4). While Helios seems to be involved in the differentiation
of (regulatory) γδTc, it is not a specific marker for suppressive
γδTc (4, 10). Thus, while freshly isolated γδTc do not express
characteristic Treg markers, the literature provides evidence that
γδTc may nevertheless exhibit regulatory activity, which will be
further described below.
REGULATORY ROLES FOR γδTC IN NON-CANCER CONTEXTS
Before focusing in on the potential regulatory role of γδTc in can-
cer, it is worthwhile to consider some other contexts in which these
cells have displayed suppressive properties. For a more compre-
hensive description of regulatory roles of γδTc outside of cancer,
we recommend a recent review (10).
Immunosuppression via γδTc plays a protective role in several
contexts. For example, in pregnancy, decidual γδTc contribute to
an immunosuppressive milieu enabling successful implantation
and protecting the growing fetus from attack by the mother’s
immune system (11–14). In celiac disease, patients on a gluten-
free diet have enhanced suppressor intestinal intraepithelial γδTc
that protect the small intestine from attack by CD8+ TCRαβ+
intraepithelial lymphocytes (IEL) via secretion of transforming
growth factor-beta one (TGF-β1); patients with active disease
have lower frequencies of these suppressor γδTc IEL (15). Lower

























































Wesch et al. Human gamma delta T regulatory cells in cancer
FIGURE 1 | γδTc exhibiting regulatory properties may be generated
in vitro by various means. Details are given in the text and the indicated
references. The γδTc are depicted in red, αβTc in green, B cells in blue,
dendritic cells in yellow, and senescent cells in gray. Ag, antigen; APC,
antigen-presenting cell; BrHPP, bromohydrin pyrophosphate; fresh, freshly
isolated; Ig, immunoglobulin; IPP, isopentenyl pyrophosphate; Mito C,
mitomycin C; PBMC, peripheral blood mononuclear cell; PWM, pokeweed
mitogen; SE, Staphylococcus aureus enterotoxins. (A) Patel et al., (B) Kuhl
et al., Peters et al., (C) Casetti et al., (D)Traxlmayr et al., (E) Li et al., (F) Peters
et al., and (G) Hua et al.
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peripheral blood γδTc numbers, more specifically a decreased
proportion of central memory γδTc, are correlated with systemic
lupus erythematosus pathogenesis, suggesting a protective role
for regulatory γδTc in this autoimmune disease as well (16). Of
note, Vδ1Tc/Vδ2Tc subset ratios are inverted in patients com-
pared to healthy controls (i.e., Vδ1Tc predominate in blood)
(16). Similarly, a higher Vδ1Tc/Vδ2Tc ratio may contribute to the
achievement of operational tolerance in pediatric liver transplant
recipients (17).
HOW TO MAKE REGULATORY γδTC
So far, it is unknown whether specific subsets, e.g., CD27+ Helios-
expressing γδTc, are innately suppressive or whether their broad
range of functional plasticity enables suppressive activity under
certain stimulatory conditions (Figure 1). An observation com-
mon to all studies on suppressive Vδ2Tc is that they realize their
immunosuppressive potential only in the presence of antigen-
presenting cells (APC) or after co-stimulation with anti-CD28
mAb (Figures 1B,C) (2–4). CD28 and CTLA-4 are critical reg-
ulators of immunosuppressive T cells, whereby CD28 plays a dual
role in both the generation and the termination of an immune
response (18).
Freshly isolated isopentenyl pyrophosphate (IPP)-stimulated
Vδ2Tc can inhibit the proliferation of CD4+ and CD8+ αβTc
in response to strong recall antigens such as Tetanus toxoid,
superantigens such as Staphylococcus aureus enterotoxins (SE) or
alloantigens in the presence of APCs (Figure 1D) (19). How-
ever, the authors could not completely rule out low frequency
activation of αβTc by antigen-specific (e.g., Tetanus toxoid) stim-
ulation. Nevertheless, peripheral blood Vδ2Tc also suppress pro-
liferation of co-cultured CD4+ αβTc after polyclonal stimulation
by anti-CD3/CD28 mAb, which simultaneously activates αβTc
(Figure 1B) (3, 4). All in all, the presence and strength of a co-
stimulatory APC-signal seem to play an important role in the
induction of Vδ2Tc suppressive capacity (4).
While TGF-β1 alone does not induce the generation of reg-
ulatory Vδ2Tc, this switch can occur in the presence of addi-
tional cytokines (Figures 1B,C,E,F) (2, 4, 9, 16). Up to 30%
of Vδ2Tc within IPP-stimulated PBMC cultivated in the pres-
ence of TGF-β1 and interleukin (IL)-15 expressed FoxP3 (clone
259D); after subsequent cell sorting, these FoxP3+ enriched
Vδ2Tc suppressed the proliferation of anti-CD3/CD28 mAb-
simulated PBMC (Figure 1C) (2). Peters and colleagues have since
demonstrated that the observed FoxP3 expression was transient,
with a steady increase in FoxP3 over 8 days of cell culture fol-
lowed by a decrease to nearly undetectable protein levels after
16 days (4).
In contrast to the work of Casetti and colleagues, in the study
of Peters et al. TGF-β1 and IL-15 did not induce regulatory func-
tions in bromohydrin pyrophosphate (BrHPP)-expanded γδTc.
Only anti-CD3/CD28 mAb-stimulated γδTc expanded in the
presence of TGF-β1 and IL-15 were able to suppress the pro-
liferation of αβTc induced by a mixture of SE (Figure 1F) (4).
The observed suppressive activity was not dependent on FoxP3
expression but was rather dependent on the presence of initial
CD28-co-stimulation. The discrepancy between these two stud-
ies might be explained by differences in γδTc expansion as well
as stimulatory conditions in the suppression assays. Casetti et al.
used IPP-stimulated PBMC from which Vδ2Tc were sorted after
expansion, whereas Peters et al. expanded magnetically isolated,
highly purified γδTc (20). In their suppression assay, Casetti
et al. analyzed the Vδ2Tc suppression of PBMC stimulated by
anti-CD3/CD28 mAb, which could potentially activate other sup-
pressive T cell subsets within the PBMC. In contrast, Peters
and colleagues used CD25-depleted CD4+ T cells as responder
cells, which were stimulated by a mixture of SE and BrHPP-
restimulation for the co-culturedγδTc. Common to both studies is
a correlation between CD28-co-stimulation (although at different
time points) and the suppressive effect. This suggests that CD28
signaling in γδTc-mediated suppression should be examined in
more detail.
While FoxP3 and γδTc regulatory activity are not strictly con-
nected, it is worthwhile to note that FoxP3 expression can be
induced in both Vδ1Tc and Vδ2Tc subsets. Similar to Vδ2Tc,
FoxP3 was prominently induced in Vδ1Tc in the presence of
TGF-β1 and additional cytokines such as IL-2 after stimulating
PBMC with anti-γδTCR for 10 days (16). Additionally, there was
an increased expression of both TGF-β1 and its receptor (CD105)
on Vδ1Tc compared to Vδ2Tc; upon activation, TGF-β1 decreased
and CD105 increased on Vδ1Tc. The authors assumed a regulatory
role for the Vδ1 CD45−CD27+ γδTc subset due to its increased
FoxP3 expression. While they demonstrated inhibition of CD4+
T cell proliferation by CD27+ Vδ1Tc, the authors unfortunately
did not directly compare the suppressive activity of CD27+ versus
CD27− Vδ1Tc (Figure 1E) (16). In this context, the analysis of
FoxP3 expression in purified Vδ2Tc versus Vδ1Tc under different
culture conditions would be interesting.
Finally, Hua and colleagues induced regulatory Vδ1Tc in vitro,
upon stimulation of PBMC with plate-bound anti-TCRVδ1 mAb,
that expressed FoxP3 (identified by mAb clone 259D/C7) and sup-
pressed CD4+ T cell proliferation (Figure 1G) (21). The authors
suggested that Vδ1Tc FoxP3 expression was sustained by a positive
feedback loop instigated by Vδ1Tc producing TGF-β1; in addition,
Vδ1Tc secreted IL-10 (21).
In summary, it is difficult to compare these studies,
as their inherent differences in experimental design (cell
source/subset/milieu/stimuli) are further confounded by the lack
of a defined regulatory γδTc marker. However, it is clear that γδTc
can be induced to exhibit regulatory properties.
HOW DO γδTC SUPPRESS OTHER CELLS?
There are, however, some controversial data regarding mecha-
nism(s) of suppression by γδTc. Kühl and colleagues assumed
mediation by the immunosuppressive cytokines TGF-β1 and
IL-10, which were secreted by γδTc after anti-CD3/CD28 mAb
stimulation (Figure 1B). After 48 h stimulation, γδTc secreted sig-
nificantly more TGF-β1 than conventional CD4+CD25+ Tregs
(3). Unfortunately, their ELISAs did not distinguish between
TGF-β1 secretion by Vδ1Tc and Vδ2Tc; however, higher TGF-β1
mRNA levels after 3 day Concanavalin A treatment would sug-
gest that Vδ1Tc have a greater suppressive capacity than Vδ2Tc or
αβTc (3).
Peters and co-workers demonstrated that co-culture with
responder cells (CD25-depleted CD4+ αβTc) induced the
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upregulation of CD80 and CD86 as well as programed death-
ligand (PDL)-1 on stimulated Vδ2Tc, which could then inter-
act with CTLA-4 or PD-1 on responder cells, leading to their
suppression (4). Furthermore, transwell experiments suggested
cell-contact-dependence, as this process was inhibited by mAb
disrupting CD86:CTLA-4 or PDL-1:PD-1 interactions between
anti-CD3/CD28 mAb-activated Vδ2Tc and activated αβTc (4).
Interestingly, the immunosuppressive capacity of Vδ2Tc was abro-
gated by Toll-like-receptor (TLR) 2 ligands as well as by activating
αβTc with a mixture of five SE (in contrast to the publication of
Traxlmayr where only one SE was applied), which both induce
a strong Th1-response [(4, 19); Peters and Wesch, unpublished
data]. Abrogated suppression correlated with increased phos-
phorylation of Akt and NFκB in αβTc and down-regulation of
inhibitory molecules such as PD-1 and CTLA-4 (4). Similarly,
Peng and colleagues found that the regulatory γδTc phenotype
could be reversed through administration of TLR8 ligand Poly-G
(Figure 2A) (22, 23). Only ligands to TLR8 (and not TLRs 2, 3,
4, 5, 7, or 9) blocked induction of senescence observed in T cells
responding to suppression via regulatory γδTc (Figure 2A) (23).
These observations exemplify the functional plasticity of γδTc that
are influenced by the nature of a stimulus and the surrounding
cytokine milieu.
FIGURE 2 | γδTc may promote the tumor growth by different
mechanisms. (A) According to Peng and colleagues, Vδ1Tc are attracted by
IP-10 and migrate into the breast-tumor microenvironment. There they
induce the senescence of αβTc and dendritic cells (DC), thereby
suppressing an immune response. The induction of senescence can be
abrogated in a TLR8 dependent manner. (B) Vδ2Tc, activated by IL-12
secreting DC, suppress αβT cells and thereby potentially hamper an
anti-tumor response of αβTc. (C) γδ17 T cells may support tumor
progression by the promotion of angiogenesis and the induction of
myeloid-derived suppressor cells (MDSC), which in turn suppress an αβTc
immune response. The γδTc are depicted in red, αβTc in green and
senescent cells in gray.
An important question is how TGF-β1 induction of conven-
tional Tregs compares to that of regulatory γδTc. Li and colleagues
provided evidence that TGF-β1-stimulated CD25+CD27+ Vδ1Tc
exert a suppressive effect on naïve CD4+ T cells similar to classical
Tregs, and that this mechanism was cell-cell contact dependent
(16) as described for Vδ2Tc above (4).
REPORTS OF REGULATORY γδTC IN CANCER
While several studies have proven the cytotoxic capabilities of
circulating γδTc and in vitro-expanded γδTc derived thereof
[reviewed in Ref. (24–29)], γδTc tumor-infiltrating lymphocytes
(TIL) may have very different functional properties (Figure 2).
The tumor microenvironment (TME) is characterized in part by
the presence of immunosuppressive cytokines such as TGF-β1 and
IL-10 that prevent immune attack against the growing malignancy.
Thus, one might assume that this environment would support
the generation of regulatory γδTc; however, to date only very few
reports support this assumption.
In a study looking at T cells from blood and TIL from lung can-
cer patients, freshly isolated γδTc only slightly expressed FoxP3
compared to CD4+ T cell TIL, of which almost half were posi-
tive for this regulatory marker (9). Blood-derived γδTc stimulated
with anti-γδ TCR mAb for 14 days in vitro expressed only low
levels of FoxP3, regardless of whether from healthy donors or
lung cancer patients. Somewhat higher FoxP3 expression was evi-
dent in TIL-derived γδTc from renal cell carcinoma, chromaffin
tumor and especially gastric cancer, with the latter comprising
21% of expanded γδTc in the given example. Furthermore, Vδ1Tc
FoxP3 expression was greater than that of Vδ2Tc in expanded
TILs from renal cell carcinoma (9). However, the authors admit-
ted the inherent drawback that induction was detected by FoxP3
mAb clone PCH101, which is sensitive to cell activation (unlike
clone 259D) (9); this has since been further corroborated (4, 9).
While researchers attempting to characterize γδTc TIL in various
cancer contexts have investigated expression of FoxP3, they have
failed to consistently correlate its expression to regulatory func-
tion. Thus, we conclude that FoxP3 expression is an inappropriate
proxy for γδTc regulatory potential and thus should be regarded
with caution.
After vaccination, increased in vitro proliferation of Vδ2Tc from
bone and connective tissue sarcoma patients undergoing immune
therapy with autologous IL-12 secreting dendritic cells (DC; ini-
tially treated with tumor-derived soluble antigen plus lipopolysac-
charide (LPS) and interferon (IFN)-γ: Trivax) was observed. Gene
expression profiling experiments indicated an over-expression of
hydroxy-methylglutaryl-CoA reductase (HMGR) in LPS/IFN-γ-
stimulated- compared to unstimulated DC. HMGR is the rate-
limiting enzyme of the mevalonate pathway that enhanced IPP
levels leading to Vδ2Tc activation. Further in vitro studies revealed
a suppressive potential of Vδ2Tc expanded by phosphoantigens
(IPP) in the presence of IL-12 secreting DC (Figure 2B) (19).
While in vitro-expanded peripheral blood-derived γδTc kill
human breast cancer cells (30) and in vivo methods to expand
γδTc targeting breast cancer have already been employed in clin-
ical trials (31, 32), a recent study of TIL in human breast tumors
deemed γδTc the most significant predictor of negative outcome
(33). γδTc frequency was correlated with negative factors such as
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advanced tumor stage, positive lymph node status, and human epi-
dermal growth factor receptor 2 (HER2) expression. Exhaustive
statistical analysis correlated γδTc with FoxP3+ cells (identified
with clone 236A/E7) and inversely with CD8+ cytotoxic Tc, sug-
gesting a negative role for γδTc (33). However, double staining of
γδTc and FoxP3 was not done, leaving the identity of FoxP3+ cells
ambiguous, and there was no indication as to whether staining was
performed on serial sections. Furthermore, γδTc subsets were not
specified, likely due to a dearth of subset-specific antibodies suit-
able for their detection via immunohistochemistry (33). Finally,
while γδTc frequency in breast tumors may prove to be a valu-
able prognostic marker, their role in disease pathogenesis was not
determined.
This same group, however, had previously suggested regulatory
properties for Vδ1Tc TIL in breast tumors (22). γδTc TIL were
extracted from a digested human breast tumor, expanded in vitro
for 1 week in 1000 IU/ml IL-2, after which bulk TILs were main-
tained at 50 IU/ml IL-2. Tumor-reactive clones were then gener-
ated and both the bulk population and selected clones derived
thereof suppressed naïve T cell proliferation, IL-2 secretion, and
DC maturation (22). This may not reflect the case in situ. While
this study proves that Vδ1Tc can assume a regulatory phenotype,
several caveats demand attention:
Firstly, the subset prevalence of γδTc in the original tumor was
not reported and thus (regulatory) Vδ2Tc may have comprised
the majority of tumor-derived cell suspensions at the outset but
may have been subsequently eliminated by high levels of IL-2 in
the culturing process, since Vδ2Tc are known to be susceptible to
activation-induced cell death (34–36). Broad ranges of Vδ1Tc lev-
els were only determined after culturing, while Vδ2Tc percentages
were not reported (22). In a follow-up paper, recruitment of γδTc
with a regulatory phenotype was linked to high levels of IFN-γ
inducible protein 10 (IP-10) in the TME (Figure 2A); however,
Vδ1Tc and Vδ2Tc were unfortunately not distinguished (37). Sec-
ondly, the high level of IL-2 used to culture TILs may in itself have
supported expansion of a regulatory phenotype not truly reflective
of the original functional orientation of these cells. Thirdly, most
experiments were carried out with one cell line and clones derived
from a single tumor, thus cannot represent a universal truth. It is
also not clear whether the same Vδ1Tc lines were used in subse-
quent publications. While valuable insight into the plasticity and
regulatory potential of Vδ1Tc can be gleaned from these studies,
further investigation of γδTc TIL in situ are required to substan-
tiate claims of regulatory function contributing to poor patient
prognosis.
While breast-tumor TIL-derived Vδ1Tc can exhibit regula-
tory properties in vitro, Vδ1Tc TIL from other cancers have been
reported to be cytotoxic (38, 39). Polyclonal γδTc TIL lines kill
melanoma cell lines, and secrete tumor necrosis factor alpha
(TNFα) and IFN-γ (38). This functional diversity could well be
context-dependent or perhaps, as Donia and colleagues suggest,
clones with various Vγ pairings are differentially activated (39). It
is also possible that these cytotoxic γδTc TIL are simultaneously
capable of as-of-yet unnoticed regulatory functions.
Finally, an indirect regulatory role for γδTc has been reported
in colorectal cancer (CRC), whereby IL-17 secreting γδTc (γδ17)
in the TME may attract and help support immunosuppressive
myeloid-derived suppressor cells (MDSC) (Figure 2C). In vitro
experiments showed that activated inflammatory DC secrete IL-23
facilitating the generation of γδ17. DC activation is thought to be
caused by release of bacterial products through the compromised
epithelial barrier characterizing CRC. Of note, γδ17 isolated from
CRC tumors were predominantly Vδ1Tc, secreted higher levels of
IL-17 compared to normal tissue controls and did not secrete IL-4,
IL-22 or immunosuppressive IL-10 (40).
AVENUES TO EXPLORE
If γδTc TIL are indeed regulatory, it is crucial to determine whether
they are inherently so or whether factors in the TME induce this
function. If the former is true, then presumably infusion of large
numbers of cytotoxic γδTc into patients should cause no safety
concern (with respect to the further promotion of tumor growth).
However, if the latter is true, we need to find a way to target the
TME to prevent a potentially detrimental shift to a regulatory phe-
notype. Better models mimicking the human TME could help us
address this question.
Since γδTc can be induced to realize regulatory potential in var-
ious ways, including those involving cytokines typically present in
the TME, some degree of regulatory function is plausible. How-
ever, so far the evidence is scant, limited to in vitro experiments
with ex vivo expanded γδTc. Admittedly, there is an inherent dif-
ficulty in assessing the regulatory capacity of γδTc TIL in situ,
as they are only present in relatively low abundance. Ye and col-
leagues attempted to address this by performing experiments with
freshly purified γδTc from tumor tissues; however, depending on
the nature of the antibodies used for purification, γδTc function
may already have been altered (23). Finally, as discussed above,
assessment using markers such as FoxP3 should be considered
carefully because not every mAb clone detecting FoxP3 expression
denotes regulatory function.
CONCLUDING REMARKS
Clearly, a more reliable panel of markers or epigenetic signature
correlated to the regulatory phenotype of γδTc will be required
for us to assess their true function(s) in situ. Furthermore, a
clear distinction should be made between Vδ1Tc and Vδ2Tc,
which may differ dramatically in terms of plasticity and func-
tion depending on their localization and exposure to various
stimuli/cytokine milieus. γδTc can be both cytotoxic and/or reg-
ulatory; therein lies their incredible therapeutic potential in the
contexts of autoimmune diseases and cancer. A fuller under-
standing of these processes should enable us to manipulate γδTc
plasticity to ensure optimal efficacy and ultimately improve patient
outcomes.
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